BISPECIFIC ANTIBODY FOR DIRECTED DELIVERY OF TAXOL

用于紫杉醇定向递送的双特异性抗体

• 批准号: 3493114
• 负责人: Gary Steven Bignami
• 金额: $ 5万
• 依托单位: HAWAII BIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-03-11 至 1992-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493114
• 关键词: antineoplastics; antitumor antibody; chromatography; clone cells; drug delivery systems; drug design /synthesis /production; gel electrophoresis; hybrid antibody; hybridomas; immunoconjugates; immunologic assay /test; immunotoxicity; laboratory mouse; neoplastic cell; paclitaxel; protein purification; thioether

DESCRIPTION: (Adapted from the Applicant's Abstract). It is proposed to achieve the selective delivery of cytotoxic agents through the use of bispecific antibodies. Taxol is a promising new anticancer agent isolated in low yield from the bark of the Pacific yew tree, Taxus brevifolia. The applicant will prepare a thioether-linked bispecific antibody with dual specificity for taxol and human cancer cells. It is asserted that this bispecific antibody will potentiate the action of taxol in target tissue, minimize side-effects, and reduce the total amount of taxol required for effective therapy.

描述：（改编自申请人摘要）。 提出要 通过使用 双特异性抗体。 紫杉醇是一种很有前途的新型抗癌药物 从太平洋紫杉短叶红豆杉的树皮中提取的产量很低。 的 申请人将制备硫醚连接的双特异性抗体， 对紫杉醇和人癌细胞的特异性。 有人断言，这 双特异性抗体将增强紫杉醇在靶组织中的作用， 最大限度地减少副作用，并减少紫杉醇的总量， 有效的治疗。